医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

World Still in the Dark on COVID-19’s Origins, says AHF

2024年05月17日 AM05:42
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Validating concerns AIDS Healthcare Foundation (AHF) first raised in early 2021 about the work of EcoHealth Alliance and its president Dr. Peter Daszak on dangerous virus research in China, AHF fully supports the U.S. Department of Health and Human Services decision to suspend and debar the organization from receiving federal funding for failure to fully comply with transparency requirements.

AHF issued a press release on Feb. 9, 2021, raising concerns about conflicts of interest among a World Health Organization (WHO) team of scientists dispatched to Wuhan, China, to study the origins of COVID-19.

In part, the release stated: “The alleged conflict of interest stems from the connection one of the investigators, a British zoologist and EcoHealth Alliance President Dr. Peter Daszak, has with the Wuhan Institute of Virology (WIV). According to The Wall Street Journal, Dr. Daszak has worked closely with a leading virologist at WIV, Dr. Shi Zhengli, on the study of bat viruses, which from 2014, was in part funded by U.S. government grants. The institute is located just a few miles away from the wet market where Chinese authorities say SARS-CoV-2 first emerged.”

Dr. Daszak has repeatedly and unequivocally dismissed the hypothesis that COVID-19 may have spread as a result of a lab accident in Wuhan. In 2020, he co-authored a Lancet article that characterized hypotheses that diverged from the idea that COVID-19 originated in wildlife as misinformation and conspiracy theories. This dismissive position has been since repudiated by a number of scientists, and in 2022, the WHO released a report advocating for more research into the lab leak theory.

In March 2023, AHF issued a press release under the headline “No NIH Money to EcoHealth Alliance, says AHF” in response to the announcement that the National Institutes of Health (NIH) was planning to resume funding Dr. Daszak’s work. The grant was suspended in 2022 because, according to the NIH, “EcoHealth Alliance had not been able to hand over lab notebooks and other records from its Wuhan partner that relate to controversial experiments involving modified bat viruses, despite multiple requests.”

“We have consistently called attention to the lack of transparency and attempts to dismiss outright the hypothesis that COVID-19 originated as a result of research at the Wuhan lab,” said AHF President Michael Weinstein. “The question has been politicized beyond measure on all sides, but our position and intention for raising it has always been and remains that we need to find out the truth for the sake of global public health. To do that, all evidence must be examined fully, transparently, and with an open mind. Whatever the origin of COVID-19, China and EcoHealth have not made answering this important question any easier. Until we know, we are flying blind.”

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 2 million clients in 46 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

View source version on businesswire.com: https://www.businesswire.com/news/home/20240516074000/en/

CONTACT

U.S. MEDIA CONTACT:

Ged Kenslea,

Senior Director, Communications, AHF

+1 323 308 1833 work

+1.323.791.5526 mobile

gedk@aidshealth.org

Denys Nazarov,

Director of Global Policy &

Communications, AHF

+1.323.308.1829

denys.nazarov@ahf.org

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders